PROSTATE CARCINOMA
- 1 February 1994
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 45 (1) , 351-359
- https://doi.org/10.1146/annurev.med.45.1.351
Abstract
▪ Abstract Over the last several years, the development of prostate-specific antigen (PSA) testing and technical refinements of anatomic radical prostatectomy have revolutionized the care of patients with prostate cancer. Serum PSA testing often allows early diagnosis of organ-confined prostate cancer. Anatomical radical prostatectomy has a high probability of completely eradicating these tumors, with minimal long-term morbidity. Use of PSA testing after therapy confirms the long-term ability of surgery to eradicate early-stage prostate cancer.Keywords
This publication has 27 references indexed in Scilit:
- A national cancer institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancersCancer, 2010
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- Cancer statistics, 1993CA: A Cancer Journal for Clinicians, 1993
- Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseaseJAMA, 1992
- High 10-year survival rate in patients with early, untreated prostatic cancerPublished by American Medical Association (AMA) ,1992
- The relationship of prostate‐specific antigen to digital rectal examination and transrectal ultrasonography: Findings of the American cancer society national prostate cancer detection projectCancer, 1992
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Family history and the risk of prostate cancerThe Prostate, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- NATURAL HISTORY OF LOCALISED PROSTATIC CANCERThe Lancet, 1989